menu
    • menu
    [{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Nordic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Advanz Pharma","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.84999999999999998,"dosageForm":"Powder for Concentrate for Solution for Infusion\n","sponsorNew":"Advanz Pharma \/ Nordic Capital","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pharma \/ Nordic Capital"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"Farnesoid X receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Advanz Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Obeticholic Acid","moa":"FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Advanz Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0.45000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"PolyPid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Doxycycline Hyclate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Powder, Extended Release","sponsorNew":"Advanz Pharma \/ ADVANZ PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ ADVANZ PHARMA"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Applied Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Govorestat","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Omalizumab","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Golimumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.34000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Alprostadil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Advanz Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Aztreonam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Advanz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enmetazobactam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Advanz Pharma

    Menu

    Advanz Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alvotech And Advanz Sign Agreement For Eylea Biosimilar In Europe

                            Details : Under the agreement, Alvotech will develop AVT06 (Aflibercept) biosimilar to Eylea. Advanz Pharma will be responsible for registration and commercializing in Europe, except for Germany and France.

                            Brand Name : AVT06

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enmetazobactam,Cefepime

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            UK MHRA Approves Advanz Pharma Antibiotic for Complex Infections

                            Details : UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated UTIs and certain kinds of pneumonia acquired during hospital stays.

                            Brand Name : Exblifep

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 05, 2024

                            Lead Product(s) : Enmetazobactam,Cefepime

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golimumab

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Alvotech

                            Deal Size : $343.4 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe

                            Details : Advanz Pharma secures exclusive rights from Alvotech to commercialize AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT16, a proposed biosimilar to Entyvio (vedolizumab), and three additional early-stage, undisclosed biosimilar c...

                            Brand Name : AVT05

                            Molecule Type : Large molecule

                            Upfront Cash : $60.1 million

                            May 24, 2023

                            Lead Product(s) : Golimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Alvotech

                            Deal Size : $343.4 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paliperidone Palmitate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ADVANZ PHARMA Launches Palmeux®/Paliperidone 1-month Long-acting Injection Across Various European countries

                            Details : Palmeux (paliperidone palmitate) is a second-generation antipsychotic, also known as an atypical antipsychotic (simultaneous serotonin and dopamine antagonist) for the treatment of schizophrenia in adult patients.

                            Brand Name : Palmeux

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 17, 2023

                            Lead Product(s) : Paliperidone Palmitate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omali...

                            Details : Under the terms of the agreement, Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand and Alvotech will be responsible for development a...

                            Brand Name : AVT23

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 06, 2023

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Govorestat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Applied Therapeutics

                            Deal Size : $138.4 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (govorestat) in ...

                            Details : AT-007 (gavorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.

                            Brand Name : AT-007

                            Molecule Type : Small molecule

                            Upfront Cash : $10.6 million

                            January 04, 2023

                            Lead Product(s) : Govorestat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Applied Therapeutics

                            Deal Size : $138.4 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aztreonam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ADVANZ PHARMA Further Strengthens its Specialty and Hospital Business by Acquiring an Anti-Infective Portfolio...

                            Details : ADVANZ strengthens its specialty and hospital business by gaining an anti-infective portfolio from Sanofi made up of eight anti-infectives including Azactam (aztreonam), Cefotax, Claforan, Oroken, Rulid, Suprax, Wintriaxone and Colistimethate Sodique pro...

                            Brand Name : Azactam

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 03, 2022

                            Lead Product(s) : Aztreonam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline Hyclate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : PolyPid

                            Deal Size : $112.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀...

                            Details : ADVANZ PHARMA receives the exclusive rights for the commercialization of PolyPid’s lead drug candidate, D-PLEX100 (doxycycline hyclate) for the prevention of surgical site infections (“SSIs”) in abdominal and cardiac surgeries, in Europe.

                            Brand Name : D-PLEX100

                            Molecule Type : Small molecule

                            Upfront Cash : $2.6 million

                            August 03, 2022

                            Lead Product(s) : Doxycycline Hyclate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : PolyPid

                            Deal Size : $112.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obeticholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $450.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva for ...

                            Details : OCALIVA (obeticholic acid), a farnesoid X receptor (FXR) agonist, is indicated for the treatment of adult patients with primary biliary cholangitis (PBC). OCALIVA is contraindicated in PBC patients with decompensated cirrhosis.

                            Brand Name : Ocaliva

                            Molecule Type : Small molecule

                            Upfront Cash : $405.0 million

                            July 01, 2022

                            Lead Product(s) : Obeticholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $450.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obeticholic Acid,Ursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $450.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, incl...

                            Details : Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® (Obeticholic Acid) for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept.

                            Brand Name : Ocaliva

                            Molecule Type : Small molecule

                            Upfront Cash : $405.0 million

                            May 05, 2022

                            Lead Product(s) : Obeticholic Acid,Ursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $450.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth